Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: An experience from a tertiary care center in Pakistan

Zubairi, Ali Bin Sarwar; Ahmad, Hayat; Hassan, Maryam; Sarwar, Sajjad; Abbas, Aamir; Shahzad, Talha; Irfan, Muhammad

doi:10.1111/crj.12650

Cited by 12 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have reported that reduced pulmonary function, especially forced vital capacity (FVC), never smoking status, and baseline serum Krebs von den Lungen-6 (KL-6) are crucial risk factors that predict an AE of IPF [10,11,12,13]. Reduced FVC patients often have decreased normal lung area due to extensive fibrosis.…”

Section: Risk Factorsmentioning

confidence: 99%

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Kishaba

2019

Medicina

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia. Idiopathic pulmonary fibrosis is often seen in elderly men who smoke. A diagnosis of IPF is based on a combination of a detailed clinical history, specific physical examination, laboratory findings, pulmonary function tests, high-resolution computed tomography (HRCT) of the chest, and histopathology. Idiopathic pulmonary fibrosis has a heterogeneous clinical course, from an asymptomatic stable state to progressive respiratory failure or acute exacerbation (AE). Acute exacerbation of IPF has several important differential diagnoses, such as heart failure and volume overload. The International Working Group project proposed new criteria for defining AE of IPF in 2016, which divides it into triggered and idiopathic AE. On the basis of these criteria, physicians can detect AE of IPF more easily. The recent international IPF guidelines emphasized the utility of chest HRCT. In addition, two antifibrotic agents have become available. We should focus on both the management and prevention of AE. The diagnostic process, laboratory findings, typical chest imaging, management, and prognosis of AE are comprehensively reviewed in this article.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Kishaba

2019

Medicina

View full text Add to dashboard Cite

show abstract

“…The management of drug treatments of the severe COVID-19 patient is complex. The benefit/risk ratio of the pharmacologic agents used should be carefully monitored ( Zubairi et al, 2018 ; Ferrara, 2020 ). Appropriate use of medications may reduce the risk of severe COVID-19 complications and postinfection sequelae.…”

Section: Risk Factors Of Pulmonary Fibrotic/inflammatory State By Sars-cov-2mentioning

confidence: 99%

Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients

Vitiello¹,

Ferrara²

2021

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of ﬁbrotic tissue. Even among cured individuals, the presence of pulmonary fibrotic tissue may be the major cause of long-term complications of COVID-19 requiring antifibrotic therapeutic treatment even in the post-COVID-19 infection phase to accelerate the healing process and fully recover lung function. This article reviews the fibrogenic mechanism of SARS-CoV-2-induced viral damage and the antifibrotic treatments indicated to treat sequelae post COVID-19 infection.

show abstract

“…There have been reported that reduced pulmonary function especially forced vital capacity (FVC) ,never smoker and baseline serum Krebs von den Lungen-6 (KL-6) are crucial risk factors of AE of IPF [10][11][12][13]. Reduced FVC patients often have decreased normal area due to extensive fibrosis.…”

Section: Diagnosis Processmentioning

confidence: 99%

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Kishaba¹

2018

Preprint

View full text Add to dashboard Cite

Idiopathic Pulmonary Fibrosis (IPF) is most common idiopathic interstitial pneumonias. IIPF is often seen in elderly smoker man. Diagnosis of IPF is integration of detailed clinical history, specific physical examination, laboratory findings, pulmonary function test, chest high-resolution computed tomography (HRCT) and pathology. IPF have heterogeneous clinical course from asymptomatic stable state to progressive respiratory failure or acute exacerbation (AE). AE of IPF have several important differential diagnosis such as heart failure and volume overload. International working project proposed new criteria of AE of IPF in 2016. They divided into triggered and idiopathic AE. On the basis of this criteria, physician can capture AE of IPF more easily. Recent international IPF guideline emphasized the utility of chest HRCT. In addition, two anti-fibrotic agents have been available. We should pay attention to not only management of AE, but also prevention it. I review diagnostic process, laboratory findings, typical chest imaging, management and prognosis of AE.

show abstract

Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: An experience from a tertiary care center in Pakistan

Abstract: Smoking, age greater than 60 years and hypoxemia were identified as factors that increased the odds of mortality in IPF patients, whereas pirfenidone was found to lower the odds of mortality.

Cited by 12 publications

References 22 publications

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Contact Info

Product

Resources

About